KEXING BIOPHARM CO.(SH:688136) Ge Long Hui A P P·2025-09-02 09:48Core Viewpoint - Company Kexing Pharmaceutical (688136.SH) has successfully completed the first subject enrollment and administration in the Phase II clinical trial of its self-developed GB08 injection for treating pediatric growth hormone deficiency [1] Group 1: Clinical Trial Progress - The Phase II/III clinical trial titled "Evaluation of the Efficacy and Safety of GB08 Injection in Treating Pediatric Growth Hormone Deficiency" has received ethical approval from the Children's Hospital affiliated with Zhejiang University School of Medicine, with approval number 2025-IEC-0009-P-01 [1] - The trial is designed as a multicenter, randomized, open-label, positive-controlled study [1] Group 2: Product Information - GB08 injection is the company's first independently developed Class I innovative drug, designed based on clinical patient needs for pediatric growth hormone deficiency [1] - The product is an Fc fusion protein long-acting growth hormone, and it is being submitted as an "innovative biological product" under the category of therapeutic biological products [1]